Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Centrophenoxine (also known as meclofenoxate) is a cholinergic compound developed in the 1950s, primarily investigated for its potential nootropic (cognitive-enhancing) effects and as a treatment for age-related cognitive decline. There is some scientific rationale behind its use to improve "cloudy thinking" or mental clarity, especially in elderly populations. Several clinical studies, particularly from Eastern Europe and Russia, have reported modest improvements in cognitive performance, memory, and alertness in patients with mild to moderate cognitive impairment or early dementia. The proposed mechanism involves increasing acetylcholine availability in the brain and reducing lipofuscin accumulation, which is associated with aging neurons.

However, the overall quality and quantity of human clinical evidence remain limited. Most studies are small, sometimes poorly controlled, and rarely replicated in recent Western research. Systematic reviews do not provide strong, consistent support for its efficacy in otherwise healthy individuals or those with minimal cognitive symptoms. The evidence is stronger for elderly populations with mild cognitive impairment than for younger people seeking cognitive enhancement. The safety profile appears acceptable at typical doses, but the benefits are likely modest.

In summary, the use of centrophenoxine for "cloudy thinking" is supported by some scientific studies, but the evidence is not robust or widely accepted in mainstream medicine. Its use is primarily justified by early clinical research rather than large, high-quality trials.

More about Centrophenoxine
More about Thinking (cloudy)

Other ingredients used for Thinking (cloudy)

Other health conditions supported by Centrophenoxine

Products containing Centrophenoxine